Supplementary Fig. S5 from Functionally Characterizing the Renal Cell Carcinoma Tumor-Immune Microenvironment via Patient-Derived Ex Vivo Models

2026 Open access

Read full text
Authors: Neja Sirc, Johannes Smolander, Anita N. Kumari, Junhao Liu, Moon Hee Lee, Kanerva Lahdensuo, Riikka Järvinen, Sara Tornberg, Linh Lin, Hanna K. Laitinen, Jason Theodoropoulos, Jay Klievink
+6 more Tuomas K. Mirtti, Anna S. Kreutzman, Heidi M. Haikala, Petrus Järvinen, Satu M. Mustjoki, Karita Peltonen
DOI: 10.1158/2767-9764.31418272
Cited by: 0

Abstract

Anti-PD1 (Pembrolizumab), VEGFR inhibitor (Axitinib) and their combination treatment responses in the RCC patient-derived ex vivo model (Related to Fig. 5)

Fields of Study & Subjects

Renal cell carcinoma treatment Cancer Immunotherapy and Biomarkers Ferroptosis and cancer prognosis

Publication details

Publication date
26 February 2026
Language
EN